IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction
Departments of 1 Pediatrics, 2 Molecular Biology, and 3 Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas 75390; and 4 Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210 Submitted 26 July 2001 ; accepted in final form 21 April 2003 Myocard...
Gespeichert in:
Veröffentlicht in: | American journal of physiology. Heart and circulatory physiology 2003-08, Vol.285 (2), p.H597-H606 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Departments of 1 Pediatrics,
2 Molecular Biology, and
3 Surgery, The University of Texas Southwestern Medical
Center, Dallas, Texas 75390; and 4 Department of
Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210
Submitted 26 July 2001
; accepted in final form 21 April 2003
Myocardial contractile dysfunction accompanies both systemic and cardiac
insults. Septic shock and burn trauma can lead to reversible contractile
deficits, whereas ischemia and direct inflammation of the heart can
precipitate transient or permanent impairments in contractility. Many of the
insults that trigger contractile dysfunction also activate the innate immune
system. Activation of the innate immune response to infection is coordinated
by the conserved Toll/interleukin-1 (IL-1) signal transduction pathway.
Interestingly, components of this pathway are also expressed in normal and
failing hearts, although their function is unknown. The hypotheses that
Toll/IL-1 signaling occurs in the heart and that intact pathway function is
required for contractile dysfunction after different insults were tested.
Results from these experiments demonstrate that lipopolysaccharides (LPS)
activate Toll/IL-1 signaling and IL-1 receptor-associated kinase-1 (IRAK1), a
critical pathway intermediate in the heart, indicating that the function of
this pathway is not limited to immune system tissues. Moreover, hearts lacking
IRAK1 exhibit impaired LPS-triggered downstream signal transduction. Hearts
from IRAK1-deficient mice also resist acute LPS-induced contractile
dysfunction. Finally, IRAK1 inactivation enhances survival of transgenic mice
that develop severe myocarditis and lethal heart failure. Thus the Toll/IL-1
pathway is active in myocardial tissue and interference with pathway function,
through IRAK1 inactivation, may represent a novel strategy to protect against
cardiac contractile dysfunction.
heart failure; signal transduction; contractile function; genetically altered mice
Address for reprint requests and other correspondence: J. A. Thomas, Depts. of
Pediatrics and Molecular Biology, Univ. of Texas Southwestern Medical Center,
5323 Harry Hines Blvd., Dallas, TX 75390-9063 (E-mail:
James.Thomas{at}UTSouthwestern.edu ). |
---|---|
ISSN: | 0363-6135 1522-1539 |
DOI: | 10.1152/ajpheart.0655.2001 |